|
gptkbp:instanceOf
|
gptkb:antibiotic
cephalosporin
|
|
gptkbp:ATCCode
|
J01DD02
|
|
gptkbp:brand
|
Ceptaz
Fortaz
Tazicef
|
|
gptkbp:CASNumber
|
72558-82-8
|
|
gptkbp:chemicalFormula
|
C22H22N6O7S2
|
|
gptkbp:contraindication
|
hypersensitivity to cephalosporins
|
|
gptkbp:discoveredBy
|
gptkb:Glaxo_Group
|
|
gptkbp:effect
|
gptkb:Enterobacteriaceae
gptkb:Pseudomonas_aeruginosa
|
|
gptkbp:eliminationHalfLife
|
1.5–2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:generation
|
third-generation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ceftazidime
|
|
gptkbp:introducedIn
|
1984
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits cell wall synthesis
|
|
gptkbp:metabolism
|
renal
|
|
gptkbp:notEffectiveAgainst
|
gptkb:methicillin-resistant_Staphylococcus_aureus
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
allergic reactions
|
|
gptkbp:spectrumOfActivity
|
broad-spectrum
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Pseudomonas_aeruginosa
|
|
gptkbp:bfsLayer
|
6
|